Merck & Co., Inc. (NYSE:MRK – Get Free Report) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.
A number of other analysts also recently issued reports on the stock. Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a report on Wednesday, October 7th. Leerink Partners raised their price objective on Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. The Goldman Sachs Group lifted their target price on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Sanford C. Bernstein boosted their target price on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research report on Tuesday, August 4th. Finally, Berenberg Bank increased their price target on Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a research note on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $155.74.
Check Out Our Latest Analysis on MRK
Merck & Co., Inc. Price Performance
Shares of Merck & Co., Inc. stock opened at $137.75 on Tuesday. Merck & Co., Inc. has a one year low of $93.90 and a one year high of $156.92. The stock’s fifty day moving average is $145.73 and its 200 day moving average is $129.11. The stock has a market cap of $339.59 billion, a P/E ratio of 142.01, a P/E/G ratio of 6.57 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The company’s revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.58 earnings per share. Sell-side analysts anticipate that Merck & Co., Inc. will post 2.82 earnings per share for the current year.
Insider Activity at Merck & Co., Inc.
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $148.01, for a total value of $8,611,961.85. Following the transaction, the executive vice president directly owned 112,955 shares in the company, valued at $16,718,469.55. This represents a 34.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.17% of the company’s stock.
Institutional Investors Weigh In On Merck & Co., Inc.
Several hedge funds have recently modified their holdings of MRK. Curry Webb Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth $29,000. Horizons Wealth Management purchased a new stake in Merck & Co., Inc. during the third quarter valued at approximately $30,000. Bullseye Investment Management LLC purchased a new stake in Merck & Co., Inc. during the second quarter valued at approximately $27,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in Merck & Co., Inc. by 69.5% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 222 shares of the company’s stock valued at $32,000 after acquiring an additional 91 shares in the last quarter. Finally, Graney & King LLC boosted its stake in Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after acquiring an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Merck & Co., Inc. News Roundup
Investors following MRK have been watching these news items:
- Positive Sentiment: Merck raised its quarterly dividend 3.5%, from $0.85 to $0.88 per share, equivalent to $3.52 annually. The increase may appeal to income-focused investors. Merck Announces First-Quarter 2027 Dividend
- Positive Sentiment: A roundup of recent pipeline developments cited positive European regulatory opinions for expanded ENFLONSIA and WELIREG uses, plus Phase 2b data for liver-disease candidate efinopegdutide. These programs could help broaden growth beyond KEYTRUDA, though they remain at different stages of development and review. How Investors May Respond To Merck (MRK) Pipeline Progress
- Negative Sentiment: Reports noted that EVP Richard Deluca sold 58,185 shares, reducing his holdings by 34%. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in the company’s outlook. Insider Selling: Merck EVP Sells Shares
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
